HeartWare International (NASDAQ: HTWR) and Endologix (NASDAQ:ELGX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
This table compares HeartWare International and Endologix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for HeartWare International and Endologix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endologix has a consensus target price of $5.36, suggesting a potential upside of 4.63%. Given Endologix’s higher possible upside, analysts plainly believe Endologix is more favorable than HeartWare International.
Valuation & Earnings
This table compares HeartWare International and Endologix’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Endologix||$192.93 million||2.21||-$154.67 million||($0.93)||-5.51|
HeartWare International has higher earnings, but lower revenue than Endologix. HeartWare International is trading at a lower price-to-earnings ratio than Endologix, indicating that it is currently the more affordable of the two stocks.
Endologix beats HeartWare International on 5 of the 8 factors compared between the two stocks.
HeartWare International Company Profile
Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.
Endologix Company Profile
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
Receive News & Ratings for HeartWare International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International and related companies with MarketBeat.com's FREE daily email newsletter.